Last 28 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.27 | — | — | 0.07 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | — | — | — | — | — | 1.36 | 0.79 | 0.66 | 0.70 | 1.31 | 1.01 | 0.82 | 1.01 | 1.55 | 1.23 | 0.95 | 1.06 | 1.16 | 1.98 | 2.49 |
| — | — | — | — | — | — | +3.4% | -22.2% | -19.9% | -31.3% | -15.4% | -17.9% | -14.0% | -4.7% | +33.7% | -37.8% | -61.7% | -61.3% | -67.7% | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | -0.04 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | -39.9% | -36.2% | -32.2% | -25.2% | -22.5% | -16.1% | -17.5% | -13.8% | -11.8% | -11.7% | -14.3% | -11.7% | -11.1% | -8.1% | -7.7% |
| — | — | — | — | — | — | -77.4% | -124.4% | -84.1% | -82.5% | -90.3% | -38.1% | -22.8% | -17.6% | -6.8% | -43.8% | -85.6% | -65.1% | -27.3% | +71.1% | +55.2% | |
| ROA | -229.3% | -12.7% | -45.2% | 538.1% | -425.9% | -1000.2% | -25.8% | -23.7% | -21.4% | -18.0% | -16.3% | -12.1% | -14.0% | -11.3% | -9.9% | -9.5% | -11.0% | -9.4% | -9.5% | -7.3% | -7.0% |
| — | +98.7% | -75.6% | +2367.9% | -1890.4% | -5443.8% | -57.6% | -95.5% | -52.8% | -59.0% | -65.8% | -28.3% | -26.9% | -20.2% | -3.4% | -29.8% | -58.8% | -46.0% | -28.2% | +61.8% | +45.5% | |
| ROIC | — | — | — | — | — | — | -53.5% | -47.2% | -39.3% | -25.8% | -18.1% | -13.1% | -14.1% | -11.1% | -10.0% | -10.0% | -12.4% | -11.4% | -13.8% | -12.4% | -13.5% |
| — | — | — | — | — | — | -195.5% | -259.4% | -179.0% | -133.3% | -81.7% | -31.0% | -13.8% | +2.7% | +27.8% | +19.0% | +8.6% | +49.9% | +72.6% | +81.0% | +71.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 0.47 | 0.33 | 0.45 | 0.34 | 0.28 | 0.24 | 0.21 | 0.18 | 0.17 | 0.16 | 0.25 | 0.24 | 0.15 | 0.08 | 0.08 |
| — | — | — | — | — | — | +65.0% | +39.2% | +115.1% | +87.9% | +69.0% | +52.4% | -17.5% | -23.2% | +12.2% | +86.4% | +235.8% | +234.0% | +117.7% | -78.0% | -74.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 18.20 | 19.15 | 31.15 | 18.20 | 9.16 | 3.49 | 3.88 | 5.19 | 4.69 | 6.54 | 8.46 | 9.04 | 10.69 | 15.05 | 17.24 | 18.06 | 12.86 | 12.95 | 10.49 | 21.12 | 25.20 |
| — | +449.1% | +703.5% | +251.0% | +95.2% | -46.7% | -54.2% | -42.7% | -56.1% | -56.5% | -50.9% | -49.9% | -16.9% | +16.2% | +64.4% | -14.5% | -49.0% | -56.8% | -66.0% | +338.9% | +192.3% | |
| Quick Ratio | 18.20 | 19.15 | 31.15 | 18.20 | 9.16 | 3.49 | 3.88 | 5.19 | 4.69 | 6.54 | 8.46 | 9.04 | 10.69 | 15.05 | 17.24 | 18.06 | 12.86 | 12.95 | 10.49 | 21.12 | 25.20 |
| — | +449.1% | +703.5% | +251.0% | +95.2% | -46.7% | -54.2% | -42.7% | -56.1% | -56.5% | -50.9% | -49.9% | -16.9% | +16.2% | +64.4% | -14.5% | -49.0% | -56.8% | -66.0% | +338.9% | +192.3% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VOR stock.
Vor Biopharma Inc.'s current P/E is -0.3x. The average P/E over the last 1 quarters is 0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Vor Biopharma Inc.'s business trajectory between earnings reports.